NCT07694947

Brief Summary

Asthma is a chronic heterogeneous inflammatory airway disease affecting millions worldwide and remains a major global health burden. Despite advances in pharmacological therapy, a substantial proportion of patients continue to experience uncontrolled symptoms due to persistent airway inflammation and disease heterogeneity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

July 4, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 10, 2026

Completed
Last Updated

July 10, 2026

Status Verified

July 1, 2026

Enrollment Period

6 months

First QC Date

July 4, 2026

Last Update Submit

July 4, 2026

Conditions

Allergic Asthma

Keywords

Allergen immunotherapyEosinophil cationic proteinSubcutaneous immunotherapy

Outcome Measures

Primary Outcomes (1)

  • Clinical response

    The change in total asthma symptom score (TASS) following subcutaneous allergen immunotherapy (SCIT) from baseline to 6 months.

    6 months

Study Arms (1)

Patients with Allergic asthma indicated for immunotherapy

EXPERIMENTAL

Patients above 18 years old and diagnosed with allergic asthma that was partially controlled under standard medical therapy. Patients were selected based on clinical stability and confirmed diagnosis supported by pulmonary function testing.

Drug: Allergen Immunotherapy Extract

Interventions

Allergen Immunotherapy ExtractDRUG

Patients diagnosed with allergic asthma that was partially controlled under standard medical therapy indicated for allergen immunotherapy

Also known as: Subcutaneous allergen immunotherapy
Patients with Allergic asthma indicated for immunotherapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age above 18 years and diagnosed of allergic asthma. Patients were clinical stabile and confirmed diagnosis supported by pulmonary function test.

You may not qualify if:

  • pregnant
  • parasitic infestations
  • recent acute asthma exacerbation
  • current smoking
  • severe persistent asthma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mohamed AbdElmoniem

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Interventions

Desensitization, Immunologic

Intervention Hierarchy (Ancestors)

Immunosuppression TherapyImmunotherapyImmunomodulationBiological TherapyTherapeuticsImmunologic TechniquesInvestigative Techniques

Study Officials

  • Mohamed AbdElmoniem

    Lecturer of chest medicine faculty of medicine Mansoura university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer faculty of medicine

Study Record Dates

First Submitted

July 4, 2026

First Posted

July 10, 2026

Study Start

January 1, 2023

Primary Completion

July 1, 2023

Study Completion

January 1, 2024

Last Updated

July 10, 2026

Record last verified: 2026-07

Locations

EG(1)